Growing Market for Smoking Cessation and Nicotine Withdrawal Products

Jul.19.2022
The smoking cessation market has grown with innovations in products and increased awareness of health risks, expected to reach $27.84 billion by 2031.

According to analysis of smoking cessation industry statistics from the past few decades by TMR market research company, the use of smoking cessation products to help smokers quit has increased, primarily including skin patches and oral products. The smoking cessation and nicotine withdrawal market is expected to reach $27.84 billion by 2031. The target audience is becoming more aware of the health burden associated with smoking, as smoking-related illnesses lead to premature deaths every year.


Innovative marketing campaigns that promote the availability and effectiveness of various smoking cessation products have raised awareness of the benefits of quitting smoking, leading to an expansion of the market for tobacco cessation and nicotine replacement companies. National research institutions in the United States and United Kingdom are heavily supporting research on tobacco-related diseases. Due to these factors and market trends, smoking cessation programs in Europe have seen significant growth, expanding the market for smoking cessation products.


A series of studies have emphasized the effectiveness of e-cigarettes in smoking cessation therapy, which has broadened the perspective of the smoking cessation and nicotine withdrawal market. Over the years, the number of young people seeking to quit smoking has significantly increased, which has expanded commercial avenues for gum, lozenges, inhalers, nasal sprays, and nicotine patches. The target audience's understanding of smoking cessation products through online channels has also been increasing, which has promoted the growth of the smoking cessation and nicotine withdrawal market.


The primary findings of the market research on smoking cessation and nicotine withdrawal.


Increased demand for both over-the-counter (OTC) and prescription products, including those designed to alleviate the health burdens of smoking and nicotine, is being driven by a focus on reducing smoking- and nicotine-related health issues. This demand has also spurred growth in the nicotine replacement therapy (NRT) market, which has become an effective tool for smoking cessation and nicotine addiction treatment. Over the past several decades, new smoking cessation aids have been introduced to the market, particularly in the US and UK. Notably, e-cigarettes play a crucial role in smoking cessation, with companies relying on advances in nicotine technology to convince smokers to successfully switch to vaping.


The widespread sales of nicotine replacement therapy (NRT) products driving income growth: For many years, NRT products have been widely adopted in key markets such as the United States. A business intelligence study by TMR found that NRT lozenges, patches, and gum have increased in commercialization in the smoking cessation and nicotine withdrawal market. Additionally, in 2020, NRT product sales saw significant growth in Europe and North America, driving market growth for smoking cessation and nicotine addiction treatment.


Smoking and Nicotine Cessation Market: Key Drivers


The increasing burden of health issues caused by tobacco and nicotine products is a key driver in the market. It is important to note that smoking-related illnesses lead to millions of premature deaths each year.


Electronic cigarettes are becoming increasingly popular and are beneficial for users who want to quit smoking. Their effectiveness is enhanced when used in conjunction with counseling, behavioral therapy, and medication. There is a growing market for smoking cessation products and nicotine replacement therapy (NRT) products that are expanding the avenues for quitting smoking and overcoming nicotine addiction.


In 2020, North America took a leading position in the global smoking cessation and nicotine withdrawal market, with the United States offering significant revenue opportunities for market participants.


Europe is another lucrative market region. Over the years, the implementation of anti-smoking initiatives in certain areas and the rapid adoption of nicotine-containing smoking cessation products have created a significant source of revenue.


The Asia-Pacific region is witnessing a colossal market, and noteworthy is the incredible untapped avenue that manufacturers of NRT (nicotine replacement therapy) products are discovering in the region.


I am sorry, I cannot do that as the original text in unclear. Please provide me with the text you want me to translate.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
business accounting for 68.5% of sales. A new controlling investment in a Western European distributor and plans to scale modern oral nicotine pouches point to a broader international strategy spanning channels and multiple product categories.
Special Report
Aug.14
Malaysia Police Seize RM12.7 Million in Illegal Vapes and Cigarettes as Probe Points to Sea Shipments From China
Malaysia Police Seize RM12.7 Million in Illegal Vapes and Cigarettes as Probe Points to Sea Shipments From China
Police in Malaysia’s Selangor state seized illegal vape products and contraband cigarettes worth about RM12.7 million (approximately $3 million) in two enforcement operations. According to New Straits Times and The Star, the vape-related operation uncovered 131,036 boxes of vape products, 4,900 bottles of e-liquid and 25,510 vape devices, valued at about RM9.4 million. Police said preliminary investigations indicated that some illegal vape products entered Malaysia through sea shipments from China before moving through storage and distribution networks.
Aug.10
Philip Morris Romania Executive on Smoke-Free Strategy: How IQOS Spaces Are Moving Beyond Retail to Consumer Connection
Philip Morris Romania Executive on Smoke-Free Strategy: How IQOS Spaces Are Moving Beyond Retail to Consumer Connection
In an interview with Romanian marketing publication IQads, Marek Gębski, Director of Smoke-Free Products at Philip Morris Romania, said IQOS experience spaces are evolving from traditional retail locations into platforms for consumer engagement and brand connection. Through locations such as IQOS Boutique Victoriei, PMI aims to use design, culture and consumer experiences to strengthen communication with adult consumers about smoke-free products. The interview highlights how tobacco companies are expanding smoke-free strategies beyond products toward experiential marketing and consumer relationships.
Aug.11
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03